Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 sep 2006 - 13:31
Statutaire naam
Crucell N.V.
Titel
Sanofi Pasteur Broadens Pandemic Preparedness With First Clinical Trial Of Novel PER.C6®-based H7N1 Vaccine
Bericht
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. The H7N1 vaccine was produced at sanofi pasteur’s Marcy l’Etoile facility in France using Crucell’s PER.C6® cell-based technology, allowing an alternative production process expected to offer advantages over traditional manufacturing methods.
Datum laatste update: 01 september 2024